Innovative Platform pixlbio utilizes cutting-edge AI-powered phenomics and high-throughput imaging to provide predictive cellular models, offering a unique value proposition to pharma companies seeking advanced drug discovery tools.

Expanding Model Portfolio The company is actively expanding into cardiac and renal models, opening new opportunities for partners interested in diverse organ-specific disease research and toxicity testing.

Major Industry Trust Trusted by eleven of the top twenty pharma firms and leading biotechs, pixlbio has established credibility, making it a reliable partner for innovative drug safety and efficacy profiling.

Growth Potential With recent collaborations and new phenotypic screening services launched in early 2024, there is significant potential for additional partnerships and service uptake across the drug development pipeline.

Funding & Certifications Supported by UK investment funding and maintaining ISO 9001:2015 certification, pixlbio demonstrates both financial stability and a commitment to quality that can facilitate new business collaborations.